Looks like this will give us further efficacy clues while helping us to learn more about the drug. If this goes well the pivotal phase 2 success will be baked in at least in my mind.
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint
Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%